Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | TYR | P14679 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23387425 | 0.85 | CA2 (0.56) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL30799247 | 0.85 | CA2 (0.56) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL1080898 | 0.83 | ALDH1A1 (0.48) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL29808702 | 0.83 | ALDH1A1 (0.48) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL27825271 | 0.81 | CA2 (0.52) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL29644929 | 0.81 | GABRA1 (0.56) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL580699 | 0.81 | GABRA1 (0.56) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL29488108 | 0.80 | CA2 (0.56) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL3169896 | 0.80 | CA2 (0.56) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 | |
| SCHEMBL105824 | 0.79 | ALDH1A1 (0.45) | ALDH1A1ALOX15CYP2C9TYRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040987-B2 | Penam derivatives for treating bacterial infections | TENNOR THERAPEUTICS LIMITED (CN) | 2021-06-22 | — | — | US | disclosed |
| EP-2318477-B1 | ADDITIVES TO PREVENT DEGRADATION OF CYCLIC ALKENE DERIVATIVES | FUJIFILM ELECTRONIC MAT USA INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-8252704-B2 | Additives to prevent degradation of cyclic alkene derivatives | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110259242-A1 | Additives to Prevent Degradation of Cyclic Alkene Derivatives | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2373604-A2 | PRODUCTION OF SUBSTITUTED PHENYLENE AROMATIC DIESTERS | Dow Global Technologies LLC (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7985350-B2 | Additives to prevent degradation of cyclic alkene derivatives | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2318477-A1 | ADDITIVES TO PREVENT DEGRADATION OF CYCLIC ALKENE DERIVATIVES | FujiFilm Electronic Materials USA, Inc. (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20110091651-A1 | Additives to Prevent Degradation of Cyclic Alkene Derivatives | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7871536-B2 | Additives to prevent degradation of cyclic alkene derivatives | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2011-01-18 | — | — | US | disclosed |
| WO-2010078512-A2 | PRODUCTION OF SUBSTITUTED PHENYLENE AROMATIC DIESTERS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010005937-A1 | ADDITIVES TO PREVENT DEGRADATION OF CYCLIC ALKENE DERIVATIVES | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-20090291210-A1 | Additives to Prevent Degradation of Cyclic Alkene Derivatives | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-4011181-A | POLYURETHANE FOAMS CONTAINING STANNOUS CATECHOL DERIVATIVES | OLIN CORPORATION (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040987-B2 | Penam derivatives for treating bacterial infections | BPGM, BLVRB, PREP | ALDH1A1 1966/4885ALOX15 1635/4885CYP2C9 1880/4885 |
| US-20110259242-A1 | Additives to Prevent Degradation of Cyclic Alkene Derivatives | GPX4, GPX1, NFE2L2 | ALDH1A1 69/4885ALOX15 82/4885CYP2C9 581/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | ALDH1A1 1061/4885ALOX15 1541/4885CYP2C9 3172/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | ALDH1A1 1061/4885ALOX15 1541/4885CYP2C9 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.